Cerity Partners LLC Sells 122,380 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Cerity Partners LLC trimmed its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 49.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,839 shares of the medical research company's stock after selling 122,380 shares during the period. Cerity Partners LLC owned approximately 0.07% of IQVIA worth $22,362,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of IQV. Continuum Advisory LLC increased its stake in IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after purchasing an additional 64 shares in the last quarter. ST Germain D J Co. Inc. grew its stake in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Zions Bancorporation N.A. grew its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after acquiring an additional 85 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of IQVIA by 10.7% during the 4th quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock worth $182,000 after acquiring an additional 90 shares in the last quarter. Finally, Private Trust Co. NA grew its stake in shares of IQVIA by 22.4% during the 1st quarter. Private Trust Co. NA now owns 536 shares of the medical research company's stock worth $94,000 after acquiring an additional 98 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQV traded down $2.80 during midday trading on Friday, reaching $162.73. 1,156,699 shares of the stock were exchanged, compared to its average volume of 1,660,352. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19. The company has a market cap of $28.15 billion, a P/E ratio of 22.17, a PEG ratio of 1.81 and a beta of 1.30. The stock's 50 day simple moving average is $151.96 and its 200 day simple moving average is $171.98.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The company had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter last year, the firm earned $2.54 earnings per share. The company's revenue was up 2.5% on a year-over-year basis. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

IQV has been the subject of several analyst reports. Mizuho decreased their target price on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Robert W. Baird decreased their target price on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. UBS Group decreased their target price on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Evercore ISI raised their target price on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $222.45.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.